{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:46:42Z","timestamp":1775123202309,"version":"3.50.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 73-year-old man with metastatic pancreatic neuroendocrine tumor was evaluated with <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT for peptide receptor radionuclide therapy. Both PET-positive and negative lesions were seen in the liver, along with extrahepatic metastases. Histopathology was obtained from one of the PET-negative liver lesions to exclude secondary malignancy. Histology confirmed a well-differentiated (G2) metastasis of pNET with high somatostatin receptor expression. We initiated peptide receptor radionuclide therapy with close monitoring of the PET-negative liver metastases. We present a rare case, where posttherapeutic scintigraphy revealed vigorous uptake of <jats:sup>177<\/jats:sup>Lu-DOTATATE even in the <jats:sup>68<\/jats:sup>Ga-DOTATATE PET-negative liver metastases. Follow-up PET\/CT showed a partial response to therapy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004888","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T16:06:02Z","timestamp":1698336362000},"page":"e585-e587","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["177Lu-DOTATATE (Lutathera) Therapy in 68Ga-DOTATATE PET\/CT-Negative Liver Metastases of a Neuroendocrine Tumor"],"prefix":"10.1097","volume":"48","author":[{"given":"David","family":"Ventura","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Muenster"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Roll","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Muenster"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Udo","family":"Kasper","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Clemenshospital Muenster, Muenster, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Muenster"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Stegger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Muenster"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","year":"2017","journal-title":"JAMA Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]Octreotate: toxicity, efficacy, and survival","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I\u2013II study","volume":"38","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2967\/jnumed.119.234054","article-title":"Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","year":"2021","journal-title":"Eur J Cancer"},{"key":"bib8-20250621","first-page":"242","article-title":"Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin","volume":"1","year":"1989","journal-title":"Lancet"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-Fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:08:05Z","timestamp":1750532885000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004888","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,23]]}}}